Literature DB >> 24341728

Association between ghrelin gene (Leu72Met) polymorphism and ghrelin serum level with coronary artery diseases.

Akbar Hedayatizadeh-Omran1, Alireza Rafiei, Rezvan Khajavi, Reza Alizadeh-Navaei, Vahid Mokhberi, Kambiz Moradzadeh.   

Abstract

Research shows that ghrelin gene polymorphism has some association with coronary artery diseases (CAD). Due to genetic differences among nations and the high prevalence of CAD, we conducted this study to examine the possible association between the polymorphism of ghrelin gene Leu72Met and CAD among an Iranian population. This case-control study was undertaken with patients who were referred to referral heart center, in 2011, with chest pain or a positive exercise test. Patients with risk factors for heart disease or who were surgery candidates, who underwent angiography and echocardiography, were also included. DNA extractions were performed using a modified salting out method, and the ghrelin region was amplified using polymerase chain reaction. The presence of the Leu72Met polymorphism and the serum levels of ghrelin were determined using the restriction fragment length polymorphism method and the enzyme-linked immunosorbent assay, respectively. The results indicated that in CAD patients, the incidence of heart failure was significantly different between the groups with genotypes CC or AA+CA (p=0.041). Mean serum level of ghrelin in the CAD group was significantly higher than that in the control group (p<0.0001). Additionally, there was a significant relationship between the distribution of ghrelin genotypes and serum levels of ghrelin in both the CAD and control groups (p<0.0001). This study indicates that there was a significant association between heart failure in CAD patients and the presence of the polymorphism, as well as an increase in serum levels of ghrelin associated with genotype distribution such that ghrelin levels have an inverse relationship with the frequency of the CC genotype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24341728     DOI: 10.1089/dna.2013.2218

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

1.  Association between pre-chemotherapy serum levels of vitamin D and clinicopathologic findings in gastric cancer.

Authors:  Akbar Hedayatizadeh-Omran; Ghasem Janbabaei; Reza Alizadeh-Navaei; Omolbanin Amjadi; Jeyran Mahdavi Izadi; Versa Omrani-Nava
Journal:  Caspian J Intern Med       Date:  2020-05

2.  Role of Leu72Met of GHRL and Gln223Arg of LEPR Variants on Food Intake, Subjective Appetite, and Hunger-Satiety Hormones.

Authors:  Tania Sanchez-Murguia; Nathaly Torres-Castillo; Lisset Magaña-de la Vega; Saraí Citlalic Rodríguez-Reyes; Wendy Campos-Pérez; Erika Martínez-López
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

3.  TP53 single nucleotide polymorphism (rs1042522) in Iranian patients with coronary artery disease.

Authors:  Versa Omrani-Nava; Akbar Hedayatizadeh-Omran; Reza Alizadeh-Navaei; Vahid Mokhberi; Rozita Jalalian; Ghasem Janbabaei; Omolbanin Amjadi; Ghasem Rahmatpour; Amir Mozaffari
Journal:  Biomed Rep       Date:  2018-07-02

4.  Association of P53 gene polymorphism with gastric cancer in Northern Iran as a high-risk region.

Authors:  Akbar Hedayatizadeh-Omran; Reza Alizadeh-Navaei; Ghasem Janbabaei; Versa Omrani-Nava; Yahya Hasheminasab; Omolbanin Amjadi; Mohsen Tehrani
Journal:  Biomed Rep       Date:  2018-02-22

5.  Leu72Met and Other Intronic Polymorphisms in the GHRL and GHSR Genes Are Not Associated with Type 2 Diabetes Mellitus, Insulin Resistance, or Serum Ghrelin Levels in a Saudi Population.

Authors:  Faris Elbahi Joatar; Ali Ahmed Al Qarni; Muhalab E Ali; Abdulaziz Al Masaud; Abdirashid M Shire; Nagalla Das; Khalid Gumaa; Hayder A Giha
Journal:  Endocrinol Metab (Seoul)       Date:  2017-09

Review 6.  Research progress of ghrelin on cardiovascular disease.

Authors:  Ming-Jie Yuan; Wei Li; Peng Zhong
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.